Now It's time to transition patients to The Libre 2 Plus Sensors

Libre 2 sensor will be phased out at the end of August 2025.
Find out what you need to do >

Great Britain (GB)
My account
Login
My account


EVANS et al. study

Meta-analysis of real-world observational studies by Evans et al.1
 

Sustained Impact of Flash Glucose Monitoring

on Glycaemic Control1

The meta-analysis by Evans and colleagues evaluated 75 trials encompassing >30,000 participants with type 1

(n = 28,063; 62 trials) and type 2 diabetes (n = 2,415; 13 trials) (T1D and T2D) using the FreeStyle Libre system
over periods from 1 to 24 months.

Use of the FreeStyle Libre system significantly reduced HbA1c levels in adults and children with T1D and in adults
with T2D. Greater reductions in HbA1c were seen in users with higher baseline HbA1c. HbA1c reductions were
sustained for 24 months in adults and children with T1D and for 12 months in adults with T2D.

Significant and sustained
reduction in HbA1c with
FreeStyle Libre system1

Use of the FreeStyle Libre system was associated
with significant reductions in HbA1c that were
sustained for 24 months in adults and children with
T1D and for 12 months in adults with T2D.

Study objective

  • Extend a previous analysis of real-world reductions in HbA1c in individuals with T1D and T2D using the FreeStyle
    Libre system versus self-monitoring blood glucose2
  • Investigate whether HbA1c reductions are sustained over 24 months
  • Identify patterns of change in HbA1c for users of the FreeStyle Libre system living with T1D or T2D1

Study design and study
population

A search for relevant publications was conducted across key abstracting and indexing databases.* The search
covered the period from 2013 until December 31st 2020.

75 studies were identified that reported longitudinal
laboratory HbA1c data in participants with T1D or T2D
using the FreeStyle Libre system over periods from 1 to 24
months. All studies reported data in a manner that could be
used in a statistical meta-analysis.

For randomised controlled trials within the analysis set,
within-intervention arm results were included, but not the
between-arm results reported previously. All studies were
reported as absolute change from baseline to ensure a
consistent approach and to reflect the real-world patient-
centred outcome.

The meta-analysis centred on observed change in HbA1c at 3–4 months and 4.5–7.5 months, as well as a longitudinal
analysis up to 24 months. Mean change in HbA1c adjusted for initial HbA1c was estimated using random effects meta-
regression versus initial HbA1c by type of diabetes with type of diabetes, month, and interaction of type of diabetes and
month as fixed effects. Separate analyses were conducted for adults and children.

Study results were published online in the expert journal Diabetes Therapy in April, 2022.1

Flowchart / study selection protocol by Evans et al. (2022).

Study results 

Use of FreeStyle Libre system resulted in significant and sustained reductions in HbA1c in adults with T1D or T2D and in children with T1D.

Change in HbA1c in adults at 3–4 and 4.5–7.5 months after starting the FreeStyle Libre system1

A total of 75 studies with outcomes data from 30,478 participants were included in the analysis. Meta-analysis of
overall mean change in HbA1c after starting the FreeStyle Libre system at each timepoint is shown in Table 1.


➤ In adults, reductions in HbA1c were evident 3 months after initiating FreeStyle Libre system, with a fall of HbA1c
      of -0.53% in T1D users and -0.45% in T2D users.


➤ At 4.5–7.5 months post-initiation, HbA1c was reduced by -0.42% in T1D participants and -0.59% in those with
      T2D.

Longitudinal change in HbA1c in adults with T1D and T2D1

The use of the FreeStyle Libre system resulted in a rapid and sustained reduction in HbA1c in adults with T1D and
T2D, with no significant differences observed between T1D and T2D (Figure 1).

Figure 1 – This longitudinal plot of adjusted mean change in HbA1c versus time for adults with T1D or T2D shows substantial overlap of
the confidence intervals for T2D and T1D at each timepoint.

Correlation between reductions in HbA1c and baseline HbA1c in adults1

➤ At the 4.5 – 7.5-month timepoint, every percentage point increase in mean starting HbA1c was associated with
      0.49% reduction in adult FreeStyle Libre system users with T1D (starting HbA1c > 7.2%) and an 0.35% decline
      in adult users with T2D (starting HbA1c > 6.7%) (Figure 2).

➤ These gains persisted throughout the time period for which data exist (up to 24 months in T1D, up to 12 months
      in T2D).

Figure 2 – Meta-regression analysis of mean change in HbA1c versus mean initial HbA1c as a bubble chart. The area of each bubble
represents the weight of the trial. The regression line from meta-regression random effects model is displayed.

Mean change in HbA1c over 24 months in children and adolescents with T1D1

➤ In children and adolescents using the FreeStyle Libre system, the greatest reduction in mean HbA1c (-0.54%)
      was seen after 1 month (Figure 3).

➤ This effect lessened with time up to 15 months, after which the reduction appeared to stabilize through 24
      months.

Figure 3 – Figure showing longitudinal plot of adjusted mean change in HbA1c over time for children and adolescents with T1D. The dotted
line above the adjusted baseline indicates the predicted rise in mean HbA1c with age in children and adolescents observed by Rosenbauer
et al.3

      Study limitations

➤ Only flash glucose monitoring arms were considered in this analysis, with no comparison to control
      subjects, since many of the real-world observational studies did not contain a control group.


➤ There may be a bias in the recruitment of the patients. Entry criteria were not standardised across
 the studies with few eligibility criteria specified.


➤ There is potential publication bias.


➤ Not all studies reported how missing data were handled.

Summary

Using the FreeStyle Libre system results in a significant reduction in HbA1c for adults and children with T1D and for adults with T2D1.

HbA1c in adult participants fell within the first 3 – 4 months after starting the FreeStyle
Libre system and this reduction was maintained to 24 months in users with T1D and to
12 months in users with T2D.


No significant differences in HbA1c outcomes were detected between adults with T1D or
T2D.

HbA1c in children and adolescents with T1D showed the greatest reduction 1 month
after starting FreeStyle Libre system (-0.54%), after which the effect lessened and
appeared to stabilise through 24 months; this may reflect age related changes in mean
HbA1c.


Reductions in HbA1c were correlated with baseline HbA1c in FreeStyle Libre system
users, with greater reduction seen in those with higher baseline HbA1c.

* A comprehensive list of search criteria can be found in the publication.1

Reference

1. Evans M, et al. Reductions in A1c with flash glucose monitoring are sustained for up to 24 months: A meta-analysis of 75 real-world observational studies. Diabetes Ther. 2022; 1175–1185. DOI: 10.1007/s13300-022-01253-9.

2. Evans M, et al. The impact of flash glucose monitoring on glycaemic control as measured by A1c: A meta-analysis of clinical trials and real-world observational studies. Diabetes Ther. 2020;11(1)83–95. DOI: 10.1007/s13300-019-00720-0..

3. Rosenbauer J, et al. Improved metabolic control in children and adolescents with type 1 diabetes. Diabetes Care. 2012;35:80–6.

Error 500 Modal
Myfreestyle Landing Page
Myfreestyle Landing Page Secure
Login Page
Ext Session Modal
Why FreeStyle Libre Systems?
Libre Products
Scientific Resources & Education
Libre Academy
Libre Hub
Help & Support
Abbott

The sensor housing, FreeStyle Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorisation of Abbott Laboratories, except to identify the product or services of the company.

This website and the information contained herein is intended for use by residents of the UK. The product images are for illustrative purposes only.

©️ 2025 Abbott Laboratories Limited. All rights reserved.

Registered Number: 329102 England. Registered Office: Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4XE

Please click "Accept Sale/Sharing and Targeted Advertising" to enable full site functionality.

At this time, we are experiencing problems with broken links on our site. As an interim solution, for full site functionality you must enable functional and advertising cookies. If you continue to opt-out of these cookies, some content on our site may not be viewable.

We use functional cookies to analyze your use of the site, improve performance and provide a better customer experience. We use advertising cookies to allow us, through certain data assigned and obtained from the user's device, to store or share with third parties information related to user's browsing activity in our website, in order to create an advertising profile and place relevant advertising in our website or those third parties websites. For more information about how Abbott uses cookies please see our Cookie Policy and Privacy Policy

In order to accept functional and advertising cookies, please click "Enable Cookies" and then click "Accept Sale/Sharing and Targeted Advertising" to view the full site.

Collapse
Learn more about cookies

Do you want to leave this page?

The "Yes" link below will take you to a website other than Abbott Laboratories. Links to other websites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the content of such websites or any link contained in such websites. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement by Abbott Laboratories of the site.

Do you want to leave this page?

This website is only for medical professionals who live and practice in the UK.

If you're a healthcare professional located in a different country, please select your country's website from the list of our global sites or contact your local Abbott representative for correct information about the products available in your country.

If you're not a healthcare profressional, click here to go to the FreeStyle Libre consumer website for the UK.